Bind Therapeutics Inc. (NASDAQ:BIND) Receives $6.00 Consensus Price Target from Analysts
Shares of Bind Therapeutics Inc. (NASDAQ:BIND) have been assigned an average rating of “Hold” from the six research firms that are currently covering the company. Five research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $6.00.
Several research analysts have recently commented on BIND shares. Stifel Nicolaus reaffirmed a “hold” rating on shares of Bind Therapeutics in a report on Wednesday, July 6th. Zacks Investment Research cut shares of Bind Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, July 11th.
Shares of Bind Therapeutics (NASDAQ:BIND) opened at 0.78 on Friday. Bind Therapeutics has a 12 month low of $0.35 and a 12 month high of $5.24. The firm’s 50 day moving average is $0.52 and its 200 day moving average is $1.17.
A hedge fund recently bought a new stake in Bind Therapeutics stock. Jacobs Levy Equity Management Inc. purchased a new stake in Bind Therapeutics Inc. (NASDAQ:BIND) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 89,900 shares of the company’s stock, valued at approximately $198,000. Jacobs Levy Equity Management Inc. owned 0.43% of Bind Therapeutics at the end of the most recent quarter.
About Bind Therapeutics
BIND Therapeutics, Inc is a biotechnology company. The Company is engaged in developing targeted therapeutics, primarily for the treatment of cancer. The Company’s product candidates are based on polymeric nanoparticles called ACCURINS, which are engineered to target specific cells and tissues in the body at sites of disease.
Receive News & Stock Ratings for Bind Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bind Therapeutics Inc. and related stocks with our FREE daily email newsletter.